NCT07009860 Phase 2 Active not recruiting
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) Study sponsor: Altimmune, Inc. · ALT
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2027-09-30 Estimated
Enrollment · participants 121 Actual
Source updated 2026-08-17 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-08-17 · 5 fields changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24
+ Updated value measure: Relative (%) reduction in liver stiffness by VCTE compared to baseline
The saved outcome text may be shortened. Check the source for full wording.
Participant count type Recorded edit − Previous value Estimated
Enrollment · participant count Recorded edit − Previous value count: 100; type: ESTIMATED
+ Updated value count: 121; type: ACTUAL
Primary completion date Recorded edit − Previous value 2027-03-31
+ Updated value 2027-09-30
Recruitment status Recorded edit − Previous value Recruiting
+ Updated value Active not recruiting
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial